Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA)
The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
This review summarizes the evidence for a hypertensinogenic effect of Erythropoietin (Epo) in normal human subjects and predialysis, hemodialysis, and continuous ambulatory peritoneal dialysis (CAPD) patients. The possible mechanisms of Epo-induced hypertension are examined with in vivo animal and in vitro data, as well as pathophysiological human studies in both normal subjects and CKD patients. The evidence for a hypertensinogenic effect of erythropoiesis-stimulating agents (ESAs) in normal subjects, predialysis CKD, hemodialysis, and CAPD patients is compelling. Epo increases BP directly and notably independently of its erythropoietic effect and its effect on blood rheology. The potential for the development of future agents that might act as specific stimulators of erythropoiesis, devoid of direct hemodynamic side effects is underscored.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NSAIDs can antagonize the effects of RAAS-inhibitors and beta blockers”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“No increase in blood pressure with aspirin”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“3/1 mm Hg increase with nonselective NSAIDs”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“No difference or an increase of up to 3/1 mm Hg with celecoxib”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“Increased odds ratio of 3.19 of hypertension with tricyclic antidepressant”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 9×
“Epo treatment showed a trend to an increased risk for hypertensive AEs by 26% as compared with no Epo/placebo, but the effect was not statistically significant.”
BackgroundInfluentialNormalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104 · cited 10×
“Epo treatment showed a trend to an increased risk for hypertensive AEs by 26% as compared with no Epo/placebo, but the effect was not statistically significant.”
BackgroundInfluentialEschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795 · cited 1×
“magnitude of the Epo-induced increase in BP (32).”
BackgroundStroke risk profile: adjustment for antihypertensive medication. The Framingham Study.
D'Agostino, R. B., Wolf, P. A., Belanger, A. J., & Kannel, W. B. (1994) · Stroke · doi:10.1161/01.str.25.1.40 · Cited by 712
Phrommintikul, A., Haas, S. J., Elsik, M., & Krum, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60194-9 · Cited by 638 · cited 1×
“Recently, another meta-analysis (24) reported the hypertension AEs in controlled trials that targeted high versus low blood Hb values and included trials previously included in a metaanalysis (21).”
BackgroundSecondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
Szczech, L. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S., Califf, R. M., Patel, U. D., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.295 · Cited by 526
Parfrey, P. S., Foley, R. N., Wittreich, B. H., Sullivan, D. J., Zagari, M. J., & Frei, D. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121039 · Cited by 373 · cited 2×
“One Hb target-controlled trial (41) did not find”
BackgroundHealth centres of today; Finsbury, Peckham.
STEWART, A. B., & Williamson, G. S. (1946) · PubMed · Cited by 256
Revicki, D. A., Brown, R. E., Feeny, D. H., Henry, D., Teehan, B. P., Rudnick, M. R., & Benz, R. L. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90122-1 · Cited by 254 · cited 1×
“96) Revicki 1995 (91) Predialysis 4/40 11/43 16.”
Casati, S., Passerini, P., Campise, M. R., Graziani, G., Cesana, B., Perisic, M., & Ponticelli, C. (1987) · BMJ · doi:10.1136/bmj.295.6605.1017 · Cited by 242
NEFF, M. S., KIM, K. E., PERSOFF, M., ONESTI, G., & SWARTZ, C. (1971) · Circulation · doi:10.1161/01.cir.43.6.876 · Cited by 221
Roger, S. D., McMahon, L. P., Clarkson, A., Disney, A., Harris, D., Hawley, C., Healy, H., Kerr, P., Lynn, K., Parnham, A., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000102471.89084.8b · Cited by 216
Ge, Y., Bagnall, A., Stricklett, P. K., Strait, K., Webb, D. J., Kotelevtsev, Y., & Kohan, D. E. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00190.2006 · Cited by 212 · cited 2×
“Chronic Epo treatment is reported to impair the vasodilatory response to endothelial NO (61) and, in 5/6 nephrectomized rats, is associated with an abrogated cGMP generation response to NO donors in vitro (60).”
BackgroundRecombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells
Carlini, R. G., Dusso, A. S., Obialo, C. I., Alvarez, U. M., & Rothstein, M. (1993) · Kidney International · doi:10.1038/ki.1993.142 · Cited by 197 · cited 1×
“Production of the vasodilating prostaglandin PGI2 (prostacyclin) is decreased and the vasoconstricting prostanoid TXB2 (thromboxane) is increased (53).”
BackgroundNovel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency
Locatelli, F., Olivares, J., Walker, R., Wilkie, M., Jenkins, B., Dewey, C., & Gray, S. J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.060002741.x · Cited by 191
Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels
Heidenreich, S., Rahn, K.-H., & Zidek, W. (1991) · Kidney International · doi:10.1038/ki.1991.31 · Cited by 183 · cited 2×
“In rat renal arterioles, the constrictive effect of Epo persisted after endothelium removal and indomethacin exposure, seemingly circumventing any direct role for endothelin, prostanoids, or nitric oxide (18).”
BackgroundLundby, C., Thomsen, J. J., Boushel, R., Koskolou, M., Warberg, J., Calbet, J. A. L., & Robach, P. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.122689 · Cited by 174
BERGLUND, B., & EKBLOM, B. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00319.x · Cited by 168 · cited 1×
“to approximately 49% in normotensive subjects were reported to be associated with a significant increase in resting mean arterial pressure (MAP) of 6 mmHg when measured by intra-arterial catheter (14), whereas a study using cuff measurements identified a significant exercise-induced increase in mean arterial pressure,…”
BackgroundStrippoli, G. F. M., Craig, J. C., Manno, C., & Schena, F. P. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000145436.09176.a7 · Cited by 152
Determinant of the optimal hematocrit
Crowell, J. W., & Smith, E. E. (1967) · Journal of Applied Physiology · doi:10.1152/jappl.1967.22.3.501 · Cited by 145 · cited 1×
“in cardiac index associated with a rise in blood viscosity (3).”
BackgroundSundal, E., & Kaeser, U. (1989) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/4.11.979 · Cited by 138
Effect of Early Correction of Anemia on the Progression of CKD
Rossert, J., Levin, A., Roger, S. D., Hörl, W. H., Fouqueray, B. L., Gassmann-Mayer, C., Frei, D. W., & McClellan, W. M. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.02.170 · Cited by 137 · cited 1×
“88) Rossert 2006 (93) Adult predialysis 22/195 26/195 8.”
* (1991) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80290-3 · Cited by 133
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients
Cody, J. D., Daly, C. D., Campbell, M., Khan, I. H., Rabindranath, K. S., Vale, L. D., Wallace, S. A., MacLeod, A. M., Grant, A., Pennington, S., et al. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003266.pub2 · Cited by 120 · cited 1×
“A third meta-analysis (26), from the Cochrane Collaboration,”
MethodEffects of erythropoietin on blood pressure.
Raine, A. E. G., & Roger, S. D. (1991) · PubMed · Cited by 117
Bode‐Böger, S. M., Böger, R. H., Kühn, M., Radermacher, J., & Frölich, J. C. (1996) · Kidney International · doi:10.1038/ki.1996.435 · Cited by 113 · cited 1×
“stricting prostanoids in modulating Epo-induced vasoconstriction (52).”
Erythropoietin Depresses Nitric Oxide Synthase Expression by Human Endothelial Cells
Wang, X. Q., & Vaziri, N. D. (1999) · Hypertension · doi:10.1161/01.hyp.33.3.894 · Cited by 108 · cited 1×
“In contrast, in human endothelial cells, Epo was demonstrated to decrease eNOS expression, which would be expected to result in decreased endothelial NO production (58).”
BackgroundC.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on Dialysis
Macdougall, I. C., Walker, R. G., Provenzano, R., de Álvaro, F., Locay, H. R., Nader, P. C., Locatelli, F., Dougherty, F. C., & Beyer, U. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00480107 · Cited by 103
Bömmer, J., Alexiou, C., Müller-Bühl, U., Eifert, J., & Ritz, E. (1987) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a091549 · Cited by 102
Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.
Abraham, P. A., & Macres, M. G. (1991) · Journal of the American Society of Nephrology · doi:10.1681/asn.v24927 · Cited by 100
Scalera, F., Kielstein, J. T., Martens-Lobenhoffer, J., Postel, S. C., Ta[Combining Diaeresis]ger, M., & Bode-Bo[Combining Diaeresis]ger, S. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090735 · Cited by 97 · cited 1×
“The mechanism is not fully elucidated but may include increased production of reactive oxygen species and asymmetric dimethylarginine, which decrease endothelial NO production (59).”
BackgroundHypertension Following Erythropoietin Therapy in Anemic Hemodialysis Patients
Buckner, F. S., Eschbach, J. W., Haley, N. R., Davidson, R. C., & Adamson, J. W. (1990) · American Journal of Hypertension · doi:10.1093/ajh/3.12.947 · Cited by 92
Vaziri, N. D., Zhou, X. J., Naqvi, F., Smith, J., Oveisi, F., Wang, Z. Q., & Purdy, R. E. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.1.e113 · Cited by 90
USA Multicenter Clinical Trial with Recombinant Human Erythropoietin (Amgen)
Eschbach, J. W., Downing, M. R., Egrie, J. C., Browne, J., & Adamson, J. W. (2015) · Contributions to nephrology · doi:10.1159/000417892 · Cited by 86
Löw, I., Grützmacher, P., Bergmann, M., & Schoeppe, W. (1989) · PubMed · Cited by 85
CELSING, F., SVEDENHAG, J., PIHLSTEDT, P., & BLOM, B. E. (1987) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1987.tb08038.x · Cited by 83 · cited 2×
“In addition, Epo-induced hypertension cannot be readily explained by higher blood viscosity because this parameter increases similarly (in relation to the resulting increase in Hct) after both Epo (17) and blood transfusions (16).”
BackgroundErythropoietin enhances vascular responsiveness to norepinephrine in renal failure
Hand, M. F., Haynes, W. G., Johnstone, H. A., Anderton, J. L., & Webb, D. J. (1995) · Kidney International · doi:10.1038/ki.1995.354 · Cited by 78 · cited 2×
“In addition, hemodialyzed subjects with Epo-induced hypertension also exhibit noradrenergic hypersensitivity (71).”
BackgroundBlood Rheology and Hypertension in Hemodialysis Patients Treated with Erythropoietin
Schaefer, R. M., Leschke, M., Strauer, B. E., & Heidland, A. (2008) · American Journal of Nephrology · doi:10.1159/000167652 · Cited by 76
Clyne, N., & Jogestrand, T. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000186797 · Cited by 75 · cited 1×
“13) Clyne 1992 (28) Predialysis 3/8 8/12 17.”
Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia
Wilcox, C. S., Deng, X., Doll, A. H., Snellen, H. G., & Welch, W. J. (1993) · Kidney International · doi:10.1038/ki.1993.261 · Cited by 67
Safety and efficacy of erythropoietin in children with chronic renal failure
Brandt, J. R., Avner, E. D., Hickman, R. O., & Watkins, S. L. (1999) · Pediatric Nephrology · doi:10.1007/s004670050583 · Cited by 67 · cited 2×
“Brandt 1999 (88) Pediatric predialysis, hemodialysis CAPD 5/23 8/21 27.”
BackgroundBlood Pressure Changes during Treatment with Recombinant Human Erythropoietin
Samtleben, W., Baldamus, C. A., Bömmer, J., Fassbinder, W., Nonnast-Daniel, B., & Gurland, H. J. (2015) · Contributions to nephrology · doi:10.1159/000416009 · Cited by 63
Erythropoietin, the FDA, and Oncology
Steinbrook, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078100 · Cited by 62 · cited 1×
“prescription sales of erythropoiesis-stimulating agents (ESAs) had reached 10 billion dollars (2).”
BackgroundBahlmann, J., Sch�ter, K. H., Scigalla, P., Gurland, H. J., Hilfenhaus, M., Koch, K. M., Muthny, F. A., Neumayer, H.-H., Pommer, W., Quellhorst, E. A., et al. (2015) · Contributions to nephrology · doi:10.1159/000419519 · Cited by 58 · cited 1×
“Bahlmann (92) 63/66 Hemodialysis Not reported Required increased BP meds: 28% Epo vs.”
BackgroundMulticenter trial of erythropoietin in patients on peritoneal dialysis.
Nissenson, A. R., Korbet, S. M., Faber, M. D., Burkart, J. M., Gentile, D. E., Hamburger, R. J., Mattern, W. D., Schreiber, M., Swartz, R. D., & Stone, J. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v571517 · Cited by 56
Bode‐Böger, S. M., Böger, R. H., Kühn, M., Radermacher, J., & Frölich, J. C. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199204002-00009 · Cited by 52 · cited 1×
“An extrarenal or systemic effect to blunt endothelial NO production, combined with the increased ET-1 response and predominance of thromboxane over prostacyclin (see above) could explain the Epo-induced vasoconstrictive effect (51).”
BackgroundTakahashi, K., Totsune, K., Imai, Y., Sone, M., Nozuki, M., Murakami, O., Sekino, H., & Mouri, T. (1993) · Clinical Science · doi:10.1042/cs0840047 · Cited by 52
Kang, D., Yoon, K. I., & Han, D. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.11.2877 · Cited by 48 · cited 1×
“increases in Hct are associated with either unchanged (85) or nominally increased (46,77) BV in hemodialysis patients, and”
BackgroundHemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients.
Lebel, M., Kingma, I., Grose, J. H., & Langlois, S. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9197 · Cited by 45
Akizawa, T., Koshikawa, S., Takaku, F., Urabe, A., Akiyama, N., Mimura, N., Otsubo, O., Nihei, H., Suzuki, Y., Kawaguchi, Y., et al. (1988) · The International Journal of Artificial Organs · doi:10.1177/039139888801100507 · Cited by 44
The new FDA label for erythropoietin treatment: How does it affect hemoglobin target?
Fishbane, S. N., & Nissenson, A. R. (2007) · Kidney International · doi:10.1038/sj.ki.5002401 · Cited by 43
Abraham, P. A., Opsahl, J. A., Keshaviah, P., Collins, A. J., Whalen, J. J., ASINGER, R. W., McLain, L. A., Hanson, G., Davis, M., & Halstenson, C. E. (1990) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80056-4 · Cited by 43
Berns, J. S., Rudnick, M. R., Cohen, R. M., Bower, J. D., & Wood, B. C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00531.x · Cited by 42 · cited 1×
“In one of the high- versus low-dose Epo trials (NHCT Trial, 7), two of the study sites reported ambulatory BP data within subsets for 6 to 12 mo and found no intergroup differences, but the sample sizes were very small for detection of differences (n 14 to 16 per arm), and antihypertensive medications varied (22,23).”
BackgroundRECOMBINANT HUMAN ERYTHROPOIETIN IN ANAEMIC PATIENTS ON HAEMODIALYSIS
Bommer, J., Müller-Bühl, E., Ritz, E., & Eifert, J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91774-0 · Cited by 40
Hemodynamics of patients with renal failure treated with recombinant human erythropoietin.
Verbeelen, D. L., Bossuyt, A. M., Smitz, J. E. J., Herman, A., Dratwa, M., & Jonckheer, M. H. (1989) · PubMed · Cited by 38
Conlon, P. J., Kovalik, E. C., Schumm, D., Minda, S. A., & Schwab, S. J. (2000) · Renal Failure · doi:10.1081/jdi-100100885 · Cited by 37 · cited 1×
“In one of the high- versus low-dose Epo trials (NHCT Trial, 7), two of the study sites reported ambulatory BP data within subsets for 6 to 12 mo and found no intergroup differences, but the sample sizes were very small for detection of differences (n 14 to 16 per arm), and antihypertensive medications varied (22,23).”
BackgroundKanbay, M., Akçay, A., Delibaşı, T., Uz, B., Kaya, A., Koca, C., Turgut, F. H., Bavbek, N., Uz, E., Duranay, M., et al. (2007) · Advances in Therapy · doi:10.1007/bf02849903 · Cited by 36 · cited 1×
“A recent study (47) also addressed the issue of BP side effects”
BackgroundCastillo, D. D., Raij, L. R., Shultz, P. J., & Tolins, J. P. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.4.505 · Cited by 36
HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Nonhematologic Complications of Erythropoietin Therapy
Zhu, X., & Perazella, M. A. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00173.x · Cited by 34
Erythropoietin-Associated Hypertension
Baskin, S., & Lasker, N. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231418 · Cited by 32
Zhou, X., Pandian, D. V., Wang, X. Q., & Vaziri, N. D. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v86901 · Cited by 31
Prevention of Erythropoietin-Associated Hypertension
Lee, M. S., Lee, J. S., & Lee, J. Y. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.090423 · Cited by 30 · cited 1×
“epitopes (pharmacophores) on the erythropoietin protein confer independent erythropoietic and hemodynamic effects (50).”
BackgroundSuzuki, M., Hirasawa, Y., Hirashima, K., Arakawa, M., Odaka, M., Ogura, Y., Yoshikawa, Y., Sanaka, T., Shinoda, A., & Morii, H. (2015) · Contributions to nephrology · doi:10.1159/000417894 · Cited by 29
Hori, K., Onoyama, K., Iseki, K., Fujimi, S., & Fujishima, M. (1990) · PubMed · Cited by 29
Müller, R., Steffen, H., Brunner, R., Saric, J., Pollok, M., Baldamus, C. A., & Kaufmann, W. (1991) · PubMed · Cited by 29
Editorials: Recombinant Human Erythropoietin: Has Treatment Reached its Full Potential?
Fishbane, S. N. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00109.x · Cited by 28
Erythropoietin and hypertension.
Nowicki, M. P. (1995) · PubMed · Cited by 27
Klinkmann, H., Wieczorek, L., & Scigalla, P. (1993) · Artificial Organs · doi:10.1111/j.1525-1594.1993.tb00571.x · Cited by 25
Effects of Recombinant Human Erythropoietin Treatment in End-Stage Renal Failure Patients
Pollok, M., Bömmer, J., Gurland, H. J., Koch, K. M., Schoeppe, W., Scigalla, P., & Baldamus, C. A. (2015) · Contributions to nephrology · doi:10.1159/000417896 · Cited by 23
Onoyama, K., Kumagai, H., Takeda, K., Shimamatsu, K., & Fujishima, M. (1989) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/4.11.966 · Cited by 22
Nonnast-Daniel, B., Deschodt, G., Brunkhorst, R. R., Creutzig, A., Bahlmann, J., Shaldon, S., & Koch, K. M. (1990) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/5.6.444 · Cited by 22
Książek, A., Wt, Z., & Książek, P. (2001) · PubMed · Cited by 22
Vasoactive effects of erythropoietin on human placental blood vessels in vitro
Resch, B. E., Gáspár, R., Sonkodi, S., DS, Falkay, G., & DSc (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.211 · Cited by 21 · cited 2×
“This Hct- and blood viscosity-independent effect of Epo on BP may be caused by arterial vasoconstriction, as was demonstrated in vitro in rat renal and mesenteric arterioles (18) and in human placental arteries and veins (19).”
BackgroundResultCardiovascular Effects of Increasing Hemoglobin in Chronic Renal Failure
Mayer, G. J., & Hörl, W. H. (1996) · American Journal of Nephrology · doi:10.1159/000169007 · Cited by 21 · cited 8×
“ESA Versus Transfusion-Induced Alterations in Hemodynamic Parameters Consistent with the observations that correction of anemia in ESRD patients by Epo induces hypersensitivity to norepinephrine and angiotensin II, as well as increased ET-1 concentration and impaired endothelial relaxation (20), several studies have s…”
BackgroundInfluentialHypertension as a Possible Complication of Recombinant Human Erythropoietin Therapy
Brunkhorst, R. R., Nonnast-Daniel, B., Koch, K. M., & Frei, V. (2015) · Contributions to nephrology · doi:10.1159/000419521 · Cited by 21
CHRONIC NITRIC OXIDE INHIBITION AGGRAVATES HYPERTENSION IN ERYTHROPOIETIN-TREATED RENAL FAILURE RATS
Moreau, C., Larivière, R., Kingma, I., Grose, J. H., & Lebel, M. (2000) · Clinical and Experimental Hypertension · doi:10.1081/ceh-100101998 · Cited by 19
Annuk, M., Linde, T., Lind, L., & Fellström, B. (2005) · Nephron Clinical Practice · doi:10.1159/000088308 · Cited by 19 · cited 2×
“Nevertheless, in both normal subjects and predialysis CKD subjects, an acute Epo injection was found to significantly impair endothelium-dependent vasodilation as evidenced by an attenuated forearm blood flow response to methacholine (20).”
BackgroundErythropoietin-induced antinatriuresis mediated by angiotensin II in perfused kidneys.
Brier, M. E., Bunke, C. M., Lathon, P. V., & Aronoff, G. R. (1993) · Journal of the American Society of Nephrology · doi:10.1681/asn.v391583 · Cited by 16
Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
Yamakado, M., Umezu, M., Nagano, M., & Tagawa, H. (1991) · PubMed · Cited by 16
ALLERGY IN CYSTIC FIBROSIS NURSES TO PANCREATIC EXTRACT
Lipkin, G., & Vickers, D. W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91775-2 · Cited by 13
Kuriyama, S., Otsuka, Y., Iida, R., Matsumoto, K., & Hosoya, T. (2007) · Clinical and Experimental Nephrology · doi:10.1007/s10157-006-0446-3 · Cited by 13
Furuland, H., Linde, T., Sandhagen, B., Andrén, B., Wíkström, B., & Danielson, B. G. (2005) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590500192355 · Cited by 12 · cited 1×
“In addition, Epo-induced hypertension cannot be readily explained by higher blood viscosity because this parameter increases similarly (in relation to the resulting increase in Hct) after both Epo (17) and blood transfusions (16).”
BackgroundAdverse Events of Subcutaneous Recombinant Human Erythropoietin Therapy
Klinkmann, H., Schmidt, R., Wieczorek, L., & Scigalla, P. (2015) · Contributions to nephrology · doi:10.1159/000421456 · Cited by 12 · cited 1×
“Klinkmann (43,44) 181/181 Both reports refer to the same data) Hemodialysis Not reported Serious AE HTN: 10.”
BackgroundStefanidis, I., Mertens, P. R., Wurth, P., Bach, R., Makropoulos, W., Mann, H., & Heintz, B. (2001) · The International Journal of Artificial Organs · doi:10.1177/039139880102400608 · Cited by 12
Erythropoietin and Other Blood-Boosting Methods
Pommering, T. L. (2007) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.04.007 · Cited by 11 · cited 1×
“In addition, Epo administration to top endurance athletes such as long-distance runners, and cyclists, although illegitimate, has reached the point where the largest and most successful teams in the Tour de France were reported to have provided Epo to their athletes on a systematic basis (1).”
BackgroundABDULHADI, M. H., Fouad-Tarazi, F. M., Thomas, T., Bravo, E. L., & Paganini, E. P. (1990) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/5.suppl_1.102 · Cited by 11
Müller, R., Steffen, H., Brunner, R., Pollok, M., Baldamus, C. A., & Kaufmann, W. (1991) · Journal of Molecular Medicine · doi:10.1007/bf01797612 · Cited by 7
Cited by
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
2020 International Society of Hypertension global hypertension practice guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002453 · Cited by 1,283
Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia
Kuhn, V., Diederich, L., Keller, T. C. S., Kramer, C. M., Lückstädt, W., Panknin, C., Suvorava, T., Isakson, B. E., Kelm, M., & Cortese-Krott, M. M. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6954 · Cited by 469
“Indeed, it was shown that EPO administration to normovolemic anemic patients increased systemic vascular resistance and arterial blood pressure and decreased cardiac output due to diminished heart rate and venous return (103, 194).”
Provenzano, R., Besarab, A., Sun, C. H., Diamond, S. A., Durham, J. H., Cangiano, J. L., Aiello, J. R., Novak, J. E., Lee, T., Leong, R., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06890615 · Cited by 290
“6% of treated patients) was below what has been reported for similar patient populations treated with ESAs (16%–32%) (35,36) and comparable with placebo rates seen in other similar studies in this patient population (37).”
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P., Ferro, C. J., Halimi, J.-M., Heine, G. H., Jadoul, M., Jarraya, F., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw433 · Cited by 229
Metadata
- Authors
- Krapf, R., & Hulter, H. N.
- Affiliations
- University of Basel (CH)
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-02
- Volume
- 4
- Issue
- 2
- Pages
- 470-480
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2130991130
- Cited by
- 180
- References
- 88
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 11 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 9 · 2014: 13 · 2013: 15 · 2012: 8
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- erythropoietin, erythropoiesis-stimulating agents, hypertension, hemodialysis, continuous ambulatory peritoneal dialysis, chronic kidney disease, blood pressure, hemorheology, erythropoiesis
- MeSH terms
- Anemia, Animals, Arteries, Blood Pressure, Chronic Disease, Erythropoietin, Hematinics, Renal Dialysis, Humans, Hypertension, Kidney Diseases, Peritoneal Dialysis, Continuous Ambulatory, Risk Assessment, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.